Special Issue

Antibiotic-Free Antibacterial Strategies Enabled by Nanomaterials

Message from the Guest Editor

In this Special Issue, we aim to showcase the most recent advances in the design and application of antibacterial nanomaterials, discuss novel antibacterial strategies, and share perspectives in shaping an antibiotic-free path to treat infections. Contributions including, but not limited to, original research papers, up-to-date reviews, and perspectives of the following and related topics are invited:

- Design and fabrication of nanomaterials for antibacterial applications;
- Nanoformulations of natural antimicrobial agents;
- Metal/metal oxide-based antibacterial nanoparticles;
- Carbon-based (e.g., graphene, CNTs, etc.) antibacterial agents;
- Nanozyme for antibacterial applications;
- Surface engineering/coating for biofilm inhibition and elimination;
- Antibacterial nanomaterials used in food science and crop protection;
- Novel nanotechnologies for antibacterial applications;
- Perspectives in the safety, regulation and translation of antibacterial nanomaterials.

Guest Editor

Dr. Hao Song

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia

Deadline for manuscript submissions

closed (30 April 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/72552

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI